Regeneron says Libtayo cuts risk of death by 37% at 44 months
Regeneron reported that Libtayo lowered the risk of death by 37% at 44 months, with a hazard ratio of 0.63. Reuters first reported the update on the drug.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Regeneron Pharmaceuticals reported new data on its drug Libtayo. After 44 months of follow-up, the risk of death fell by 37%, with a hazard ratio (HR) of 0.63. Reuters published the report.
The company also confirmed that the drug keeps providing a disease-free survival benefit, including in patients who are MRD negative.
why it matters
The data matter for Regeneron shares because they support the long-term effect of Libtayo and may shape expectations for the drug's sales and the company's position in oncology.
market impact
Regeneron (REGN): longer-lasting benefit in the data supports expectations for Libtayo sales.
tags
instruments
sources
- Regeneron Pharmaceuticals Says Libtayo Achieves 37% Reduction In Risk Of Death At 44 Months (Hr 0.63) — Reuters, 25 October 2026 at 09:17 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗